TNFSF13B and systemic lupus erythematosus: We therefore expected a higher SRI-4 response rate than the ~55% of unselected SLE patients who responded in the pivotal trials of belimumab (12, 13, 30) given the resultant raised BAFF levels following successful depletion of B-cells.